Krsnaa Diagnostics Limited

Krsn DIAGNOSTICS' 0

LET'S DO GOOD. '

Date: 11[th ] October, 2021

BSE Limited Corporate Service Department, l[5][1 ] Floor, P. J. Towers, Dalal Street, Mumbai 400 001

The National Stock Exchange of India Limited Exchange Plaza, 3[rd ] Floor, Plot No. C/1, 'G' Block, Bandra Kurla Complex, Bandra (E), Mumbai 400 051

Scrip ID: KRSNAA Scrip Code: 543328

Symbol: KRSNAA

Dear Sir / Madam,

Subject: Outcome of Board Meeting.

This is to inform you that the Board of Directors of the Company at its meeting held today, which commenced at 12:30 p.m. and concluded at 04:05 p.m., inter-alia, unanimously approved / consented / took on record the following:

Financial Results:

Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended 30[th ] September, 2021, along with Limited Review report thereon. A copy of the same is enclosed.

Change in the Key Managerial Personnel:

The resignation of CS Manisha Chitgopekar from the post of Company Secretary and Compliance Officer of the Company effective from closing of business hours on Monday, 11th October, 2021 and appointment of Mr. Nikhil Deshpande as Company Secretary and Key Managerial Personnel pursuant to the provisions of Section 203 of the Companies Act, 2013 and as Compliance Officer effective from Tuesday, 12th October, 2021, pursuant to the provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI (Prohibition of Insider Trading) Regulations, 2015.

We have enclosed, the disclosure in terms of the SEBI Circular No. CIR/CFD/CMD/4/2015 dated 9th September, 2015 as Annexure I to this letter.

Request you to take the same on your records.

Thanking you, Yours sincerely,

For Krsnaa Diagnostics Limited

(��

Pallavi Bhatevara Managing Director DIN: 03600332

==> picture [88 x 84] intentionally omitted <==

1 JC. ag i< t (Formerly known as Krsnaa Diagnostics Pvt. Ltd.) Chinchwad, Taluka - Haveli, Pune, MH - 411019 (India) • 3 t>C> 020 29780210 / 11 / 12 I [email protected] CIN: U74900PN2010PLC138068 S.No. 243/A, Hissa No. 6, CTS No. 4519, 4519/1, Near c � �gw�n� L74900PN2010PLC1 80 .. ""

www kr snaadiagno<;ti<:. corn I 11 I t1 I ti I an I l

_.I. rsna DIAGNOSTICS LET'S DO GOOD ... 0

Annexure I

Disclosures required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read along with SEBI Circular CIR/CFD/CMD/4/2015 dated 9th September, 2015

A. Resignation of Ms. Manisha Chitgopekar:

Sr. No.	Details of events thatneedstobe provided	Information ofsuchevent(s)
1 2	Reasonforchangeviz.a1313eiAtA'leAt, resignation, FeA'leval, eeatR eF etReFwise: Date of a 1313ei AtA'leAV cessation (as applicable) & teFA'l ef: a1313eiAtA'leAt:	Resignation due to health reasons. Effective from closing of business hours on Monday, 11thOctober, 2021.
3	Brief Profile (in case of appointment)	Not applicable
	Disclosure of relationships between
4	directors(in case of appointment of a	Not applicable
	director)
B.	Appointment of Mr. Nikhil Deshpande:
Sr. No.	Details of events that needs to be provided	Information of such event(s)
1	Reasonforchangeviz.appointment, FesigAatieA, FeA'leval, eeatR eF etReFwise:	Appointment.
2	Date of appointment/cessatieA (as a1313licaele) & term of appointment:	Effective from Tuesday,12thOctober, 2021.
		Nikhil has an experience of 10+ years in the
		Company Secretarial function including fund
		raising through IPO, Corporate Governance.
		Prior to joining Krsnaa, he has worked with
		leadinglistedcompanieslikeinPuneviz.
3	Brief Profile (in case of appointment)	Kinetic Engineering, ZensarTechnologies as
		well as KPIT Technologies.
		He is a law graduate and an associate member
		of the Institute of Company Secretaries of
		India.
4	Disclosure of relationships between directors(incase of appointment of a director)	Mr. Nikhil Deshpande is not related to any other Director(s) presently on the Board or any of theKeyManagerialPersonnelofthe Company.

==> picture [163 x 81] intentionally omitted <==

k I s 1 Dior ic C1 (Formerly known as Krsnaa Diagnostics Pvt. Ltd.) S.No. 243/A, Hissa No. 6, CTS No. 4519, 4519/1, Near Chinchwad Station, 020 29780210 / 11 / 12 I [email protected] CIN : U74900PN2010PLC138068 ---------------n- - ' Chinchwad, Taluka Haveli, Pune, MH -411019 (India) NEW CIN: L74900?NL010PLC l360Gd

w w w, k rs n a ad i a g nos t I cs.com I &1 I ll I �i 1 � I rJ

----

Floor 6, Building No. 1 Cerebrum[I] T Park, Kalyani Nagar Pune 411014,[I] ND[I] A Tel: +91 20 6763 34

MSKA

& Associates

Chartered Accountants

Independent Auditor's Review Report on Consolidated Unaudited Quarterly and year to date financial results of the Group pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

The Board of Directors

We have reviewed the accompanying statement of consolidated unaudited financial results of Krsnaa Diagnostics Limited ('the Holding Company'), its subsidiaries, (the Holding Company and its subsidiaries together referred to as the 'Group') for the quarter ended September 30, 2021 and the year to-date results for the period from April 01, 2021 to September 30, 2021 ('the Statement'), being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ('the Regulations'). Attention is drawn to the fact that the figures for the previous quarter ended June 30, 2021, as reported in these consolidated financial results have been approved by the Company's Board of Directors but have not been subjected to review.
This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting'('lnd AS 34'), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Head Office: 602, Floor 6, Raheja Titanium, Western Express Highway, Geetanjali Railway Colony, Ram Nagar, Goregaon (E), Mumbai 400063, INDIA, Tel: +91 22 6831 1600 Regd. No. 105047W I Ahmedabad I Bengaluru I Chennai I Goa I Gurugram I Hyderabad I Kochi I Kolkata I Mumbai I Pune www.mska.in

MSKA

& Associates

Chartered Accountants

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

This Statement includes the results of the following entities:

Sr. No 1	Name of the Company KDPL Diagnostics (Amritsar) Private Limited Relationship with the Holding Company Wholly Owned Subsidiary
2	KDPL Diagnostics (Bathinda) Private Limited Wholly Owned Subsidiary
3	KDPL Diagnostics ( Jalandhar) Private Limited Wholly Owned Subsidiary
4	KDPL Diagnostics (Ludhiana) Private Limited Wholly Owned Subsidiary
5 6	KDPL Diagnostics (Patiala) Private Limited KDPL Diagnostics (SAS Nagar) Private Limited Wholly Owned Subsidiary Wholly Owned Subsidiary
7	Krsnaa Diagnostics (Mohali) Private Limited Wholly Owned Subsidiary

The consolidated unaudited financial results include the interim financial information of Seven (7) subsidiaries which have not been reviewed by their auditors, whose interim financial information results reflect total assets of Rs. 2.69 million as at September 30, 2021 and total revenue of Rs. Nil and Rs. Nil, total net loss after tax of Rs. 0.13 million and Rs. 0.23 million and total comprehensive loss of Rs. 0.13 million and Rs. 0.23 million for the quarter ended September 30, 2021 and for the period from April 01, 2021 to September 30, 2021, respectively, and cash inflows of Rs. 2.28 million for the period from April 01, 2021 to September 30, 2021, as considered in the consolidated unaudited financial results. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

==> picture [89 x 81] intentionally omitted <==

MSKA

& Associates

Chartered Accountants

Our conclusion on the Statement is not modified in respect of the above matter.

For MSKA & Associates

Chartered Accountants

ICAI Firm Registration No.105047W Digitally signed by Nitin Jumani Date: 2021.10.11 14:56:57 -, r a, 1llllll +o5:3o

Nitin Manohar Jumani

Partner Membership No.: 111700 UDIN: 21111700AAAAFO5907

Place: Pune Date: October 11, 2021

Krsnaa Diagnostics Limited (Formerly known as Krsnaa Diagnostics Private Limited)

Statement of Unaudited Consolidated Financial Results for the quarter and hatf year ended September 30, 2021

		Quarter	ended	IINR Millfon,	excent earnlnRS oor Hatf Year ended	share)
Sr.No.	Particulars	September 30, 2021 (Unaudited)	June 30, 2021 (Unaudited/ Un reviewed. Refer Note 7)		September 30, 2021 (Unaudited)
1	Income
	Revenue from operations	1,082.63		1,324.72	2,407.35
	Other income	32.30		32.38		64.68
	Total Income	1,114.93		1,357.10	2,4n.03
2	Expenses Cost of material consumed Employee benefits expense	135.88 128.17		222.59 124.09		358.47 252.26
	Finance costs	82.14		61.21		143.35
	Depreciation and amortization expense	103.32		99.76		203.08
	Fees to hosp!tals and others Other exoenses Total Exoenses	274.13 225.09 948.73		283.11 279.87 1,070.63	557.24 504.96 2,019.36
3	Profit / (lossl before ta• 11) • 121	166,20		286.47		452.67
4	Tax expenses
	Income Tax charge	28.93		49.84		78.77
	Deferred ta, char,e/(credlt)	12.01		20.68		32.69
	Total tax expenses	40.94		70.S2		111.46
5	Profit / lloss) for the oeriod/vear (3) -14)	125.26		215.95		341.21
6	Other comprehensive income
	Items that will not be reclassified subsequently to profit and loss
	Re-measurement gains / (losses) on defined benefit plans	(0.10)		(0.10)		(0 .20)
	Income tax effect	0.02		0.02		0.04
	Total other comnrehensive income/I lossl for the neriodlvear	10.081		(0.08		10.16
7	Total comcrehensive income/Closs! for the noriod/vear, net of tax 15+6I	125.18		215.87		341.05
	Profft/(loss) for the period/year
	Attributable to:
	Equity Holders of the Holding Company	125.26		215.95		341.21
	Non Controllin" Interests
		125.26		215.9S		341.21
	Total other comprehensive lncome/(loss) for the period/year Attributable to:
	Equity Holders of the Holding Company Non Controlllne: Interests	(0.08)		(0.08)		(0.16)
		10.08		10.08		10.161
	Total comprehensive income/(loss) for the period/year
	Attributable to:
	Equity Holders of the Holding Company Non Controllin.e: Interests	125.18 125.18		215.87 215.87		341.05 341.05
8	Paid-up equity share capital (Face Value of Rs. 5/- Each)	156.99		64.95		156.99
	Earnings per share - After split (Not annualised for quarter & half year)
	8asic (Rs.)	4.51		16.62		12.28
	DIiuted fRs.)	4.47		7.94		12.17
Place: Pune Date: 11.10.2021		f:0 � � B5 � � [!} I\'. r), �Ir?��	For & on behalf of Board �;-·•·=•� 1.� allavl Bhat� anaglng Director DIN: 03600332
		--

Krsnaa Diagnostics Limited (Formerly known as Krsnaa Diagnostics Private Limited)

Notes to Unaudited Consolidated Financial Results:

These unaudited consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Holding Company at its meeting held on October 11, 2021. 2. The above Statement has been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) 2015, as amended. 3. The Holding Company is converted from Private Limited Company to Public Limited Company, pursuant to Special Resolution passed in extraordinary general meeting of the shareholders held on April 25, 2021 & consequently the name of the Company has been changed to Krsnaa Diagnostics Limited pursuant to fresh certificate of Incorporation issued by Registrar of Company dated May 6, 2021. 4. The Holding company has invested Into seven special purpose vehicles (SPVs) which are wholly owned subsidiaries namely, - KDPL Diagnostics (Ludhiana) Private Limited on March 22, 2021, KDPL Diagnostics (Amritsar) Private Limited on March 24, 2021, KDPL Diagnostics (Bathlnda) Private Limited on March 24, 2021, KDPL Diagnostics (Jalandhar) Private Limited on March 24, 2021, KDPL Diagnostics (Patiala) Private Limited on March 25, 2021, KDPL Diagnostics (SAS Nagar) Private Limited on March 25, 2021 and Krsnaa Diagnostics (Mohali) Private Limited on July 27, 2021 The company has remitted the amount towards subscription of share capital In these SPVs on April 12, 2021 & August 21, 2021. In the absence of the necessary agreement being executed and transfer of funds for subscription of share capital of these subsidiaries by March 31, 2021 the Holding Company has not consolidated the SPVs In its financial statement for the vear ended March 31. 2021. 5. The Holding Company, pursuant to shareholders' resolution dated April 25, 2021, sub-divided Its equity share capita I by sub-dividing the face value of the Equity Shares from �10 to '!.5 per Equity Share. Accordingly, the issued and paid-up capita I of our Company was sub-divided from 6,494,964 Equity Shares of '!.10 each to 12,989,928 Equity Shares of '!.5 each. 6. Pursuant to resolution passed at the meeting of Board of Director's held on July 23, 2021, 1,42,01,600 equity shares were issued to compulsory convertible preference shareholders of series A and series C In the ratio 2:1 7. The Holding Company has completed Initial Public Offer (IPO) of 1,27,31,605 Equity Shares of the face value of Rs. 5/- each at an Issue price of Rs. 954/- per Equity Share to non employee category shareholders and Rs. 861/- per Equity Share to employee category shareholders, comprising offer for sale of 85,25,520 equity shares by selling shareholders and fresh issue of 42,06,085 equity shares. The Equity Shares of the Company were listed on August 16, 2021 on BSE Limited and National Stock Exchange of I ndla Limited. The total offer expenses have been proportionately allocated between the selling shareholders and the Holding Company as per respective offer size. The Holding Company was not mandatorily required to prepare and publish quarterly results up to the period ended June 30, 2021. Accordingly, the figures for the quarter ended June 30, 2021 have been approved by the Company's board of director but were not subject to limited review or audit by the statutory auditors of the company. 8. The Group's operations predominantly relate to providing Radiology and Pathology services for X Ray, CT Scan, MRI, Mammography, Tele- Reporting Services, and all type of Blood and Urine Investigation. The Chief Operating Decision Maker (CODM) reviews the operations of the Company as one operating segment. Hence no separate segment information has been furnished herewith. 9. The management has made an assessment of the Impact of COVID-19 on the Group operations, financial performa nee and position as at and for the quarter & six months ended September 30, 2021 and has concluded that the impact is primarily on the operational aspects of the business. In making the assessment management has considered the recoverability of trade receivables, investment and other assets and also considered the external and internal information available up to the date of approval of these financial results Including status of existing and future customer orders, cash flow projections etc. and concluded that there is no significant Impact which is required to be recognized in the financial results. Accordingly, no adjustments have been made to the financial results. 10. The Code on Social Security 2020 ('the Code') relating to employee benefits, during the employment and post-employment, has received Presidential assent on September 28, 2020. The Code has been published in the Gazette of India. Further, the Ministry of Labour and Employment has released draft rules for the Code on November 13, 2020. However, the effective date from which the changes are applicable Is yet to be notified and rules for quantifying the financial Impact are also not yet Issued. The Group will assess the impact of the Code and will give appropriate impact in the financial statements in the period In which, the Code becomes effective and the related rules to determine the financial Impact are published.
Previous period figures have been regrouped/ rearranged wherever considered necessary.

For & on behalf of Board �c;NOS7tc �[<::j] Krsnaa Diagnostics Limited � � PUNE (� �} �� � a<'. * * Pallavi Bhatevara Place: Pune C'1-ft,.,.. flYl..,l"�,Jtf> ' ' Managing Director Date: 11.10.2021 DIN: 03600332 <::> ( 1')l �

Krsnaa Diagnostics Limited (Formerly known as Krsnaa Diagnostics Private Limited) Consolidated Balance Sheet as at September 30, 2021 Paricular I.ASSETS Non-urrent assots Property, plant and equipment Capital work-in-progress Intangible assets Financial assets Investments loans Other financial assets Other non-current assets Total non-currant assets Current assets Inventories Financial assets Trade receivables Cash and cash equivalents Bank balances other than cash and cash equivalent Other financial assets Other current assets Total current assets Total Assets II.EQUIT AND LIABILITIES Equity Equity share capital Other equity Non·controlling interest Total equity Liabilities Non--urrent liabilitios Financial liabilities Borrowings Other financial liabllltles Employee benefit obligations Other non-current liabilities Deferred Tax Liabilities Total non-current liabilities Current liabilities Financial liabilities Borrowings Trade payables i)total outstanding dues of micro enterprises and small enterprises ll)total outstanding dues of creditors other than micro enterprise and small enterprise Other financial liabilities Employee benefit obligations Other current liabilities TotaIcurrent liabilities Total Liabilities Total Equity and Liabilities Place: Pune Date: 11.10.2021 � < � : B PUNE .= �w �c ,�,	(INR MIiiin.) Asat September 30, 2021 (Unaudited) 3,063.02 195.23 7.30 2.90 145.59 2.81 202.32	(INR MIiiin.) Asat September 30, 2021 (Unaudited) 3,063.02 195.23 7.30 2.90 145.59 2.81 202.32
		3,619.17

		95.50 1,070.04 343.10 3,454.14 91.63 96.30
		S,150.71
		8,769.88
		156.99 6,291.97
		6,448.96
		362.03 67.29 6.14 29.48 139.59
		604.53
		128.55 4.36 952.07 242.64 9.17 379.60
		1,716.39


	aav aevaa Managfng Director DIN: 03600332

Krsnaa Diagnostics limited

(Formerly known as Krsnaa Diagnostics Private Limited)

Statomont of Consolidatod cash Flows for tho Half year anded September 30, 2021

Statomont of Consolidatod cash Flows for tho Half year anded Septe	mber 30,	2021
			(INR MIiiion.)
			Six Month, ended
Particulars			September 30,	2021
			(Unaudited)
cash flow from operating activities
Profit/(Loss) for the period				452.67
Adjustments for:
Depreciation and amortization expenses				203.08
Finance cost				143.35
Interest income				(52.08)
Loss on Sale/Disposal of Assets
Provision for doubtful trade receivable balances				5.45
Gain on fair value movement of Compulsory Convertible Preference Share
Employee stock option scheme compensation				7.25
Operating profit before working capital changes				759.72
Changes in working capital
(Decrease)/lncrease in trade payables				32.06
Decrease/(increase) in inventories				(23.40)
Oecrease/(lncrease) in trade receivables				(350.92)
(Decrease)/increase In other current liabilities				340.48
(Decrease)/ Increase in other non current llabllltles				(3.55)
(Decrease)/ Increase in other financial liabilities				3.40
(Decrease)/ increase In Employee Payables				0.64
(Decrease)/ increase in provisions
(Decrease)/ increase in other current financial liabilities				(3.96)
Decrease/ (increase) In other current financial assets				(29.33)
Decrease/ (increase) in non current financial assets				(10.15)
Decrease/ ({ncrease) in other current assets				(3.04)
Decrease/ (increase} In other non current assets				4.83
cashgeneratedfrom/(usod) inoperations				716.78
Income tax paid				(69.71)
Income tax refund received				82.01
Not cash flows generated from /(used) In operating activities (Al				729.08
B. cash flow from Investing activities
Payment for property, plant and equipment and Intangible assets				(530.45)
Proceeds from sale of property, plant and equipment and Intangible assets
Investment In term deposits with banks (having original maturity of more than		three months)	(2,150.51)
Interest received				79.89
Not cash flow (used)inInvesting activities (Bl			(2,601.07)
C, Cash flow from Financing activities
Proceeds from Issuance of equity share capital				4,000.00
Proceeds/(Repayment) of borrowings			(1,779.34)
Share Issue expenses				(107.14)
Interest paid				(145.18)
Not cash flow generated from /(used) in financing activities (C)				1,96B.34
Not increase in cash and cash oqulvalonts (A+B+c)				96.35
cash and cash equivalents at tho beginning of the period				246.75
cash and cash equivalents at tho end of the period				343.10
cash and cash oqu!valents comprise: Balances with banks On current accounts Bank Overdraft Account (Debit Balance) Cash on hand Less: Bank and book overdraft Total cash end bank balances at end of the period Place: Pune Date: 11.10.2021	- �GNOS7t, B � � li PUNE � � t:, C'0'7NCH't"I�*		332.46 0.33 10.31 343.10 For & on behalf of Board .. "'"'"' ,.� � � Pallavl Bhatevara Managing Director DIN: 03600332

Floor 6, Building No. 1 Cerebrum[I] T Park, Kalyani Nagar Pune 411014,[I] ND[I] A Tel: +91 20 6763 34

MSKA

& Associates

Chartered Accountants

Independent Auditor's Review Report on unaudited quarterly and year to date standalone financial results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

The Board of Directors